At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 110 enrolled
Drug / intervention
maridebart cafraglutide +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 133 in Subjects With Obesity
In Brief
A Phase 1 clinical trial evaluating maridebart cafraglutide and Placebo for Obesity. Completed, enrolled 110 participants across 3 sites.
Detailed Summary
The study aims to assess the safety and tolerability of maridebart cafraglutide as single and multiple doses in participants with obesity
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartAug 2020
Primary CompletionNov 2022
TodayJul 2026
First PostedJul 21, 2020
Enrollment StartAug 7, 2020
Primary CompletionNov 18, 2022
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 5.9 years ago
Interventions
maridebart cafraglutidebiological
Participants will receive maridebart cafraglutide as a single dose in Part A and multiple doses in Part B and C.
Placebodrug
Participants will receive placebo as a single dose in Part A and multiple doses in Part B.